Key facts
- It has raised $139.2M across 4 recorded rounds; the latest was Early Stage VC ($11.8M) in Apr 2018.
- Notable investors include Wellington Management, Cormorant Asset Management, Deerfield Management, Pfizer Ventures, MSD Global Health Innovation Fund — 14 tracked in total.
- Strata Oncology has filed 4 Form Ds with the SEC since 2016, most recently Nov 2024 ($6.1M sold to 14 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Strata Oncology
Funding rounds
4 roundsAbout Strata Oncology
Operator of an oncology company intended to accelerate the impact of precision medicine for patients with cancer. The company partners with major healthcare systems across the country, which systematically send their cancer patients' biopsies to high-throughput CLIA labs for genomic sequencing, with results provided to the oncologist within days, indicating the tumor profile, and matching appropriate therapies and drug trials, enabling healthcare providers to provide actionable insight to the lives of cancer patients.
- Sector
- Healthcare
- HQ
- Ann Arbor, MI, United States
- Founded
- 2015
- Employees
- 82
- Website
- strataoncology.com/
- Ownership
- Privately Held (backing)
Strata Oncology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Strata Oncology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Strata Oncology in its N-PORT filings yet. We sweep new filings monthly.